Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EMvision Medical Devices Ltd. ( (AU:EMV) ) has provided an update.
S&P Dow Jones Indices has updated its March 2026 quarterly rebalance for the All Ordinaries, reversing the previously announced inclusion of African Gold Limited and the removal of American Rare Earths Limited. The index will instead see a range of additions across sectors, including technology, media, mining, energy transition, and medical devices, with changes effective before trading opens on March 23, 2026.
The revised constituent list brings in companies such as 4DMedical, Cettire, Southern Cross Media Group, Saluda Medical, and multiple resources and energy-related stocks, including Galan Lithium, Lake Resources, and Marimaca Copper. These adjustments may shift index exposures toward critical minerals, energy transition themes, and select growth names, with potential implications for passive funds and benchmark-aware investors tracking the All Ordinaries.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
More about EMvision Medical Devices Ltd.
S&P Dow Jones Indices is a leading global provider of financial market indices, including the All Ordinaries, a benchmark index tracking a broad selection of companies listed on the Australian Securities Exchange. Its index reviews and constituent changes influence portfolio composition, index-tracking funds, and benchmark comparisons for institutional and retail investors.
Average Trading Volume: 36,027
Technical Sentiment Signal: Sell
Current Market Cap: A$146.8M
Find detailed analytics on EMV stock on TipRanks’ Stock Analysis page.